Literature DB >> 16205710

Host and virus determinants of picornavirus pathogenesis and tropism.

J Lindsay Whitton1, Christopher T Cornell, Ralph Feuer.   

Abstract

The family Picornaviridae contains some notable members, including rhinovirus, which infects humans more frequently than any other virus; poliovirus, which has paralysed or killed millions over the years; and foot-and-mouth-disease virus, which led to the creation of dedicated institutes throughout the world. Despite their profound impact on human and animal health, the factors that regulate pathogenesis and tissue tropism are poorly understood. In this article, we review the clinical and economic challenges that these agents pose, summarize current knowledge of host-pathogen interactions and highlight a few of the many outstanding questions that remain to be answered.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16205710     DOI: 10.1038/nrmicro1284

Source DB:  PubMed          Journal:  Nat Rev Microbiol        ISSN: 1740-1526            Impact factor:   60.633


  116 in total

1.  The 3A protein from multiple picornaviruses utilizes the golgi adaptor protein ACBD3 to recruit PI4KIIIβ.

Authors:  Alexander L Greninger; Giselle M Knudsen; Miguel Betegon; Alma L Burlingame; Joseph L Derisi
Journal:  J Virol       Date:  2012-01-18       Impact factor: 5.103

2.  Complete genome sequence of a novel picornavirus, canine picornavirus, discovered in dogs.

Authors:  Patrick C Y Woo; Susanna K P Lau; Garnet K Y Choi; Cyril C Y Yip; Yi Huang; Hoi-Wah Tsoi; Kwok-Yung Yuen
Journal:  J Virol       Date:  2012-03       Impact factor: 5.103

3.  Differential effects of the putative GBF1 inhibitors Golgicide A and AG1478 on enterovirus replication.

Authors:  Lonneke van der Linden; Hilde M van der Schaar; Kjerstin H W Lanke; Johan Neyts; Frank J M van Kuppeveld
Journal:  J Virol       Date:  2010-05-26       Impact factor: 5.103

4.  Discovery of Structurally Diverse Small-Molecule Compounds with Broad Antiviral Activity against Enteroviruses.

Authors:  Jun Zuo; Steve Kye; Kevin K Quinn; Paige Cooper; Robert Damoiseaux; Paul Krogstad
Journal:  Antimicrob Agents Chemother       Date:  2015-12-28       Impact factor: 5.191

5.  Human astrocytic cells support persistent coxsackievirus B3 infection.

Authors:  Xiaowei Zhang; Zhenhua Zheng; Bo Shu; Xijuan Liu; Zhenfeng Zhang; Yan Liu; Bingke Bai; Qinxue Hu; Panyong Mao; Hanzhong Wang
Journal:  J Virol       Date:  2013-09-11       Impact factor: 5.103

6.  Inhibition of protein trafficking by coxsackievirus b3: multiple viral proteins target a single organelle.

Authors:  Christopher T Cornell; William B Kiosses; Stephanie Harkins; J Lindsay Whitton
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

7.  Isolation of sabin-like polioviruses from wastewater in a country using inactivated polio vaccine.

Authors:  Sebastian Zurbriggen; Kurt Tobler; Carlos Abril; Sabine Diedrich; Mathias Ackermann; Mark A Pallansch; Alfred Metzler
Journal:  Appl Environ Microbiol       Date:  2008-07-18       Impact factor: 4.792

8.  Live attenuated enterovirus vaccine (OPV) is not associated with islet autoimmunity in children with genetic susceptibility to type 1 diabetes: prospective cohort study.

Authors:  Hanna Viskari; Sami Oikarinen; Sanna Hoppu; Tytti Vuorinen; Heini Huhtala; Jorma Toppari; Riitta Veijola; Jorma Ilonen; Mikael Knip; Heikki Hyöty
Journal:  Diabetologia       Date:  2017-09-02       Impact factor: 10.122

9.  Microarray analysis reveals altered circulating microRNA expression in mice infected with Coxsackievirus B3.

Authors:  Chaoyu Sun; Lei Tong; Wenran Zhao; Yan Wang; Yuan Meng; Lexun Lin; Bingchen Liu; Yujia Zhai; Zhaohua Zhong; Xueqi Li
Journal:  Exp Ther Med       Date:  2016-08-22       Impact factor: 2.447

10.  Interactions between viral and prokaryotic pathogens in a mixed infection with cardiovirus and mycoplasma.

Authors:  Peter V Lidsky; Lyudmila I Romanova; Marina S Kolesnikova; Maryana V Bardina; Elena V Khitrina; Stanleyson V Hato; Frank J M van Kuppeveld; Vadim I Agol
Journal:  J Virol       Date:  2009-07-15       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.